Small and Medium Biopharmaceutical Enterprises in North America and Europe - Biotechnology Clusters, Funding Characteristics and Regulatory Landscape
Publisher Name » GBI Research
Published Date » 2010-02-15
No. Of Pages » 84
GBI Research, the leading business intelligence provider, has released its latest research, “Small and Medium Biopharmaceutical Enterprises in North America and Europe - Biotech Clusters, Funding Characteristics and Regulatory Landscape.” This pharmaceutical and healthcare report provides an overview of the small and medium biopharmaceutical enterprises in the North American and European regions. The report provides an insight in to the importance of Small and Medium Enterprises (SME) in the biotechnology industry. It covers market characterization, geographical spread of SMEs, drivers and restraints, regulatory scenarios and funding challenges faced by the biotechnology SME industry. The study reviews the role of SMEs in driving the pipeline within the biotechnology industry, the role of governments in promoting the sector, as well as potential gaps. It provides a comprehensive analysis of the deals in the SME sector and also provides competitive benchmarking to understand how SMEs compete.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.
Scope
The scope of this report includes:
- Biotechnology SME composition in North America, and Europe. In North America, the US (United States) and Canada are covered. The report covers European countries such as the UK (United Kingdom), Germany, Canada, France, Sweden, Switzerland, Denmark, the Netherlands and Belgium.
- Pipeline analysis data for the two geographies to provide an understanding of the contribution of biotechnology SMEs in the pipeline of the industry.
- Qualitative analysis of market drivers and restraints and funding for SMEs. Funding structure for biotechnology SMEs and issues faced in funding.
- Analysis of deals involving biotechnology SMEs.
- Competitive landscape covering key players Clovis Oncology, Pacific Biosciences, ActoGeniX, Aileron, BioVex, AC Immune, Avila Therapeutics, Chroma Therapeutics, KaloBios, Achaogen.
Reasons to buy
The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:
- Develop an understanding of the SME biotechnology sector and the role played by them in driving innovation in the pharmaceutical and biotechnology industries.
- Understand the funding related issues that SMEs face and make use of the potential solutions.
- Exploit in-licensing and out-licensing opportunities by identifying the key areas of licensing activities of SME biotechnology firms.
- Understand and exploit M&A opportunities present in the biotechnology SME landscape.
- Develop a clear knowledge & understanding of how SMEs are supported in North America and Europe.
- Identify key players best positioned to take advantage of the emerging market opportunities.
Table of contents
1 Table of contents
1 Table of contents
1.1 List of Tables
1.2 List of figures
2 Introduction
2.1 GBI Research Report Guidance
3 Small and Medium Biopharmaceutical Enterprises - Overview of the Present Biotechnology SME Sector
3.1 Small and Medium Enterprise Characteristics
3.1.1 SMEs Across Different Industries and Geographies are Small Enterprises
3.1.2 SMEs Have an Entrepreneurial Management Structure in Place with Central Leadership Allowing Quick Decision Making
3.1.3 Biotechnology SMEs are Non-Profit Making Companies Due to a Lack of a Marketed Product Portfolio
3.1.4 SMEs Lack Commercialization Capabilities and Should Focus on Industry Partnerships and Outsourcing
3.2 Lifecycle of a Small and Medium Enterprise
3.3 Small and Medium Enterprise and Patents
3.4 Biotechnology Clusters and Role in Development of SME
3.4.1 European Clusters
3.4.2 North American Clusters
3.4.3 Success Factors for Clusters
4 Small and Medium Biopharmaceutical Enterprises - Market Characterization
4.1 Composition of the Biotechnology Industry: Small and Medium Enterprises Dominate
4.1.1 Composition of SMEs by Geography: North America has Higher Proportion of Biotechnology Companies
4.1.2 Composition of SMEs by Size: The Majority of SMEs are Small, Employing Less than 250 Employees
4.1.3 Composition of SMEs by Therapeutic Class: Most SMEs are Active in Cancer Research
4.1.4 Biotechnology Drug Pipeline: SME Contribution Important
4.2 Drivers and Restraints
4.2.1 Drivers
4.2.2 Restraints/Challenges
5 Small and Medium Biopharmaceutical Enterprises - Funding Scenario
5.1 SME Lifecycle and Sources of Funding
5.1.1 Pre-Seed and Seed Stage: Angel Investor and Government Grants are the Key Sources of Finances
5.1.2 Start up Stage: Venture Capital Firms Provide Major Funding
5.1.3 Early Growth and Expansion: SMEs Feel Funding Pressure, Big Pharmaceutical and Biotechnology Companies Take an Interest
5.2 Funding Activities of SMEs
5.2.1 Venture Capital Firms: In the Absence of Exit Opportunities they are Unable to Raise Sufficient Funds for New SMEs
5.2.2 Initial Public Offerings: Slowdown in IPO Market Impacts Availability of Growth Stage Capital
5.2.3 Mergers and Acquisitions
5.3 The Future Funding Scenario of Biotechnology SMEs Looks Balanced
5.4 Gaps in SME Funding
5.5 Filling the Funding Gap
5.5.1 Government Support: Need to Increase Focus on Growing SMEs
5.5.2 Industry Players: Need to Invest Early in SMEs
5.5.3 VC and Angel Investors: To Continue their Support
6 Small and Medium Biopharmaceutical Enterprises - Regulatory Environment and Government Support
6.1.1 Overview of Regulatory Environment
6.1.2 Regulatory Environment and Small and Medium Enterprises
6.2 The Current State of Support for SMEs - Europe
6.2.1 Hard Initiatives: Grants and Funding
6.2.2 Soft initiatives - Guidance and Advice
6.3 Current State of Support for SMEs - North America
6.3.1 Funding and Assistance Structures Present in North America
6.3.2 Hard Initiatives: Grants and Funding
6.3.3 Soft Initiatives - Guidance and Advice
7 Small and Medium Biopharmaceutical Enterprises - Deals Analysis
7.1 Mergers and Acquisitions of SMEs in North America and Europe
7.1.1 Sciele Pharma acquired Addrenex
7.1.2 Celldex Therapeutics acquired CuraGen Corporation
7.1.3 Affitech AS merged with Pharmexa A/S
7.1.4 Cell Genesys and BioSante merged to form BioSante
7.1.5 Johnson & Johnson acquires Cougar Biotechnology
7.1.6 Takeda acquires IDM Pharma
7.1.7 Merck acquires Insmed's follow-on biologics platform
7.1.8 Bristol-Myers Squibb acquires Medarex
7.2 Licensing Activities: SME Pipeline Targeted for In-licensing
7.2.1 Preclinical
7.2.2 Phase I
7.2.3 Phase II
7.2.4 Phase III
7.2.5 Approved
7.3 Out Licensing of Biotechnology SMEs to Large Pharmaceutical Companies
8 Small and Medium Biopharmaceutical Enterprises in North America and Europe - Competitive Landscape
8.1 Competitive Benchmarking
8.2 Key Player Profiles
8.2.1 Clovis Oncology
8.2.2 Pacific Biosciences
8.2.3 ActoGeniX
8.2.4 Aileron
8.2.5 BioVex
8.2.6 AC Immune
8.2.7 Avila Therapeutics
8.2.8 Chroma Therapeutics
8.2.9 KaloBios
8.2.10 Achaogen
9 Small and Medium Biopharmaceutical Enterprises in North America and Europe - Conclusion
10 Appendix
10.1 Market Definitions
10.2 Abbreviations
10.3 Research Methodology
10.3.1 Coverage
10.3.2 Secondary Research
10.3.3 Primary Research
10.3.4 Expert Panel Validation
10.4 Contact Us
10.5 Disclaimer
10.6 Sources
Table 1: Definition of Small and Medium Enterprises in Key Countries 12
Table 2: Country Break-up of Healthcare Biotechnology SMEs in North America and Europe, 2009 24
Table 3: Biotechnology SMEs, Key M&A activities in 2009 51
Table 4: Biotechnology SMEs, Licensing Agreements for Drugs in the Preclinical Stage, 2009 56
Table 5: Biotechnology SMEs, Licensing Agreements for Drugs in the Phase I Stage, 2009 59
Table 6: Biotechnology SMEs, Licensing Agreements for Drugs in the Phase II Stage, 2009 61
Table 7: Biotechnology SMEs, Licensing Agreements for Drugs in the Phase III Stage, 2009 63
Table 8: Biotechnology SMEs, Licensing Agreements for Approved Drugs, 2009 65
Table 9: Benchmarking of Key Biotechnology SMEs, 2009 69
Figure 1: Lifecycle of an SME, 2010 14
Figure 2: Number of Clusters and Networks by Country in Europe, 2010 16
Figure 3: Key Biotechnology Clusters in Europe, 2010 16
Figure 4: Key Biotechnology Clusters in the US, 2010 18
Figure 5: Key Biotechnology Clusters in Canada, 2010 18
Figure 6: Factors for Success of Biotechnology Clusters, 2010 19
Figure 7: Composition of the European and North American Biotechnology Industry, Number of Companies, 2009 21
Figure 8: Composition of the European and North American Biotechnology Industry, 2009 22
Figure 9: Number of SMEs by Geography, 2009 23
Figure 10: Break-up of SME Sector by Country, 2009 23
Figure 11: SME by Size of Companies, 2009 24
Figure 12: Number of SMEs by Therapeutic Areas, 2009 25
Figure 13: Therapeutics Areas of Focus for SMEs, 2009 26
Figure 14: Number of Drugs in the Pipeline in the Biotechnology Industry, 2009 27
Figure 15: Sources of SME funding at Different Stages of its Lifecycle, 2010 30
Figure 16: Financing Activities: Biopharmaceutical and Pharmaceutical Industry, 2006-2009 32
Figure 17: Financing Activities: Biotechnology SMEs, 2006-2009 32
Figure 18: Number of Companies Receiving VC Funding, Biotechnology SMEs, 2006- 2009 33
Figure 19: Number of IPOs/Offerings, Biotechnology SMEs, 2006-2009 34
Figure 20: Number of Companies Acquired, Biotechnology SMEs, 2006-2009 35
Figure 21: Trends in Funding, 2008-2009 36
Figure 22: Filling the Funding Gap for SMEs, 2008 37
Figure 23: Decline in NME Approvals by the FDA, 19962008 40
Figure 24: European Union Funding for the Development of SMEs and Innovation, 2010 42
Figure 25: FP7 Funding Activities, 2008-2013 44
Figure 26: Government Support for SMEs, the US, 2010 46
Figure 27: Government Support for SMEs, Canada, 2010 46
Figure 28: SBIR Program Grants for Different Stages of Development of Innovation, 2010 48
Figure 29: Licensing Activity by Licensor Type, 2008-2009 54
Figure 30: Licensing Activity of Biotechnology and Pharmaceutical Companies, 2009 55
Figure 31: Licensing Activity of Biotechnology SMEs by Stage of Development, 2009 55
Figure 32: Licensing Activity of Top Ten Pharmaceutical Companies, 2004-2009 67
Figure 33: Licensing Activity of Top Ten Pharmaceutical Companies, 2004-2009 68
Figure 34: Clinical Trials Analysis for ActoGenix, 2008 72
Figure 35: Clinical Trials Analysis for BioVex, 2008 73
Figure 36: Clinical Trials Analysis for AC Immune, 2008 74
Figure 37: Clinical Trials Analysis for Chroma Therapeutics, 2008 76
Figure 38: Clinical Trials Analysis for KaloBios, 2008 77
Figure 39: Clinical Trials Analysis for Achaogen, 2008 78
Figure 40: GBI Research Methodology 82
1 Table of contents
1 Table of contents
1.1 List of Tables
1.2 List of figures
2 Introduction
2.1 GBI Research Report Guidance
3 Small and Medium Biopharmaceutical Enterprises - Overview of the Present Biotechnology SME Sector
3.1 Small and Medium Enterprise Characteristics
3.1.1 SMEs Across Different Industries and Geographies are Small Enterprises
3.1.2 SMEs Have an Entrepreneurial Management Structure in Place with Central Leadership Allowing Quick Decision Making
3.1.3 Biotechnology SMEs are Non-Profit Making Companies Due to a Lack of a Marketed Product Portfolio
3.1.4 SMEs Lack Commercialization Capabilities and Should Focus on Industry Partnerships and Outsourcing
3.2 Lifecycle of a Small and Medium Enterprise
3.3 Small and Medium Enterprise and Patents
3.4 Biotechnology Clusters and Role in Development of SME
3.4.1 European Clusters
3.4.2 North American Clusters
3.4.3 Success Factors for Clusters
4 Small and Medium Biopharmaceutical Enterprises - Market Characterization
4.1 Composition of the Biotechnology Industry: Small and Medium Enterprises Dominate
4.1.1 Composition of SMEs by Geography: North America has Higher Proportion of Biotechnology Companies
4.1.2 Composition of SMEs by Size: The Majority of SMEs are Small, Employing Less than 250 Employees
4.1.3 Composition of SMEs by Therapeutic Class: Most SMEs are Active in Cancer Research
4.1.4 Biotechnology Drug Pipeline: SME Contribution Important
4.2 Drivers and Restraints
4.2.1 Drivers
4.2.2 Restraints/Challenges
5 Small and Medium Biopharmaceutical Enterprises - Funding Scenario
5.1 SME Lifecycle and Sources of Funding
5.1.1 Pre-Seed and Seed Stage: Angel Investor and Government Grants are the Key Sources of Finances
5.1.2 Start up Stage: Venture Capital Firms Provide Major Funding
5.1.3 Early Growth and Expansion: SMEs Feel Funding Pressure, Big Pharmaceutical and Biotechnology Companies Take an Interest
5.2 Funding Activities of SMEs
5.2.1 Venture Capital Firms: In the Absence of Exit Opportunities they are Unable to Raise Sufficient Funds for New SMEs
5.2.2 Initial Public Offerings: Slowdown in IPO Market Impacts Availability of Growth Stage Capital
5.2.3 Mergers and Acquisitions
5.3 The Future Funding Scenario of Biotechnology SMEs Looks Balanced
5.4 Gaps in SME Funding
5.5 Filling the Funding Gap
5.5.1 Government Support: Need to Increase Focus on Growing SMEs
5.5.2 Industry Players: Need to Invest Early in SMEs
5.5.3 VC and Angel Investors: To Continue their Support
6 Small and Medium Biopharmaceutical Enterprises - Regulatory Environment and Government Support
6.1.1 Overview of Regulatory Environment
6.1.2 Regulatory Environment and Small and Medium Enterprises
6.2 The Current State of Support for SMEs - Europe
6.2.1 Hard Initiatives: Grants and Funding
6.2.2 Soft initiatives - Guidance and Advice
6.3 Current State of Support for SMEs - North America
6.3.1 Funding and Assistance Structures Present in North America
6.3.2 Hard Initiatives: Grants and Funding
6.3.3 Soft Initiatives - Guidance and Advice
7 Small and Medium Biopharmaceutical Enterprises - Deals Analysis
7.1 Mergers and Acquisitions of SMEs in North America and Europe
7.1.1 Sciele Pharma acquired Addrenex
7.1.2 Celldex Therapeutics acquired CuraGen Corporation
7.1.3 Affitech AS merged with Pharmexa A/S
7.1.4 Cell Genesys and BioSante merged to form BioSante
7.1.5 Johnson & Johnson acquires Cougar Biotechnology
7.1.6 Takeda acquires IDM Pharma
7.1.7 Merck acquires Insmed's follow-on biologics platform
7.1.8 Bristol-Myers Squibb acquires Medarex
7.2 Licensing Activities: SME Pipeline Targeted for In-licensing
7.2.1 Preclinical
7.2.2 Phase I
7.2.3 Phase II
7.2.4 Phase III
7.2.5 Approved
7.3 Out Licensing of Biotechnology SMEs to Large Pharmaceutical Companies
8 Small and Medium Biopharmaceutical Enterprises in North America and Europe - Competitive Landscape
8.1 Competitive Benchmarking
8.2 Key Player Profiles
8.2.1 Clovis Oncology
8.2.2 Pacific Biosciences
8.2.3 ActoGeniX
8.2.4 Aileron
8.2.5 BioVex
8.2.6 AC Immune
8.2.7 Avila Therapeutics
8.2.8 Chroma Therapeutics
8.2.9 KaloBios
8.2.10 Achaogen
9 Small and Medium Biopharmaceutical Enterprises in North America and Europe - Conclusion
10 Appendix
10.1 Market Definitions
10.2 Abbreviations
10.3 Research Methodology
10.3.1 Coverage
10.3.2 Secondary Research
10.3.3 Primary Research
10.3.4 Expert Panel Validation
10.4 Contact Us
10.5 Disclaimer
10.6 Sources
List of Tables
Table 1: Definition of Small and Medium Enterprises in Key Countries 12
Table 2: Country Break-up of Healthcare Biotechnology SMEs in North America and Europe, 2009 24
Table 3: Biotechnology SMEs, Key M&A activities in 2009 51
Table 4: Biotechnology SMEs, Licensing Agreements for Drugs in the Preclinical Stage, 2009 56
Table 5: Biotechnology SMEs, Licensing Agreements for Drugs in the Phase I Stage, 2009 59
Table 6: Biotechnology SMEs, Licensing Agreements for Drugs in the Phase II Stage, 2009 61
Table 7: Biotechnology SMEs, Licensing Agreements for Drugs in the Phase III Stage, 2009 63
Table 8: Biotechnology SMEs, Licensing Agreements for Approved Drugs, 2009 65
Table 9: Benchmarking of Key Biotechnology SMEs, 2009 69
List of Figures
Figure 1: Lifecycle of an SME, 2010 14
Figure 2: Number of Clusters and Networks by Country in Europe, 2010 16
Figure 3: Key Biotechnology Clusters in Europe, 2010 16
Figure 4: Key Biotechnology Clusters in the US, 2010 18
Figure 5: Key Biotechnology Clusters in Canada, 2010 18
Figure 6: Factors for Success of Biotechnology Clusters, 2010 19
Figure 7: Composition of the European and North American Biotechnology Industry, Number of Companies, 2009 21
Figure 8: Composition of the European and North American Biotechnology Industry, 2009 22
Figure 9: Number of SMEs by Geography, 2009 23
Figure 10: Break-up of SME Sector by Country, 2009 23
Figure 11: SME by Size of Companies, 2009 24
Figure 12: Number of SMEs by Therapeutic Areas, 2009 25
Figure 13: Therapeutics Areas of Focus for SMEs, 2009 26
Figure 14: Number of Drugs in the Pipeline in the Biotechnology Industry, 2009 27
Figure 15: Sources of SME funding at Different Stages of its Lifecycle, 2010 30
Figure 16: Financing Activities: Biopharmaceutical and Pharmaceutical Industry, 2006-2009 32
Figure 17: Financing Activities: Biotechnology SMEs, 2006-2009 32
Figure 18: Number of Companies Receiving VC Funding, Biotechnology SMEs, 2006- 2009 33
Figure 19: Number of IPOs/Offerings, Biotechnology SMEs, 2006-2009 34
Figure 20: Number of Companies Acquired, Biotechnology SMEs, 2006-2009 35
Figure 21: Trends in Funding, 2008-2009 36
Figure 22: Filling the Funding Gap for SMEs, 2008 37
Figure 23: Decline in NME Approvals by the FDA, 19962008 40
Figure 24: European Union Funding for the Development of SMEs and Innovation, 2010 42
Figure 25: FP7 Funding Activities, 2008-2013 44
Figure 26: Government Support for SMEs, the US, 2010 46
Figure 27: Government Support for SMEs, Canada, 2010 46
Figure 28: SBIR Program Grants for Different Stages of Development of Innovation, 2010 48
Figure 29: Licensing Activity by Licensor Type, 2008-2009 54
Figure 30: Licensing Activity of Biotechnology and Pharmaceutical Companies, 2009 55
Figure 31: Licensing Activity of Biotechnology SMEs by Stage of Development, 2009 55
Figure 32: Licensing Activity of Top Ten Pharmaceutical Companies, 2004-2009 67
Figure 33: Licensing Activity of Top Ten Pharmaceutical Companies, 2004-2009 68
Figure 34: Clinical Trials Analysis for ActoGenix, 2008 72
Figure 35: Clinical Trials Analysis for BioVex, 2008 73
Figure 36: Clinical Trials Analysis for AC Immune, 2008 74
Figure 37: Clinical Trials Analysis for Chroma Therapeutics, 2008 76
Figure 38: Clinical Trials Analysis for KaloBios, 2008 77
Figure 39: Clinical Trials Analysis for Achaogen, 2008 78
Figure 40: GBI Research Methodology 82
Upcoming Reports:
|
Molded Plastics Market - Global Industry Size, Market Share, Trends, Analysis And Forecast, 2012 - 2018
By - Transparency Market Research
Molded plastics have different segments such as Molded LDPE, Molded Polystyrene, Molded PVC, Molded Polypropylene Molded HDPE and Molded LLDPE. Molded HDPE resins represent the largest product segment in the molded plastics market fueled by its application in industrial packaging, while Molded LLDPE will see the fastest growth in molded plastics.
During the economic recession period of 2008 – 2010, the molded plastics market declined due to decrease in plastic consumption. This market saw a comeback due to the subsequent economic revival, recovery in GDP, rise in...
|
|
Electronic Chemical Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2012 - 2018
By - Transparency Market Research
Electronic chemicals are highly pure chemicals like strippers, gases, acids, photo resists and so on, which are useful in electronic applications like printed circuits boards (PCB), integrated circuits (IC), flat screens, and semiconductor chips. For this reason, the electronic chemical market follows the growth pattern of the electronic market and allied industries like semiconductors.
The market is categorized based on type into semiconductors, acids and solvents, printed circuit boards (PCB), CMP slurries, gases and polymers. The electronics market saw a...
|
|
Ready To Drink (RTD) Tea And Coffee Market - Global Industry Size, Market Share, Trends, Analysis And Forecast, 2012 - 2018
By - Transparency Market Research
Ready to drink (RTD) tea and coffee is a substitute for carbonated drinks and is widely gaining popularity due to fast and busy lifestyles. RTD tea is especially preferred by consumers who are health conscious, while RTD coffee is perceived as an instant energy source. RTD tea and coffee are one of the most selling products worldwide. The RTD tea and coffee market has shown remarkable growth in recent years.
Asia Pacific holds majority of the market share, closely followed by Europe. The demand for RTD tea and coffee is projected to increase in North America due to rising...
|
Research Assistance
We will be happy to help you find what you need.
Please call us or write us:
Please call us or write us:
866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.com
Email: sales@researchmoz.com
Select License type:
Share this report
Latest Reports
- The Future of the Haircare Market in Egypt to 2017
- The Future of the Haircare Market in Denmark to 2017
- Overview of international chemical market
- Russian market of microcredits and lending to SME in Russia
- Overview of furniture market
- The Future of the Haircare Market in Czech Republic to 2017
- LTE Strategy 2013 - 2018
- Natural And Synthetic (Ethoxyquin, BHA, BHT) Animal Feed Antioxidants Market For Swine, Poultry, Cattle And Aquaculture - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2012 - 2018
- Seed Treatment Market (Insecticides, Fungicides, Other Chemical And Nonchemical Treatment) For Corn, Soybean, Wheat, Canola, Cotton And Others - Global Industry Analysis, Size, Share, Growth And Forecast, 2012 - 2018
- Future of the Spanish Defense Industry - Market Attractiveness, Competitive Landscape and Forecasts to 2018
Related News
|
One-third of Massachusetts Hospitals Facing Financial Downturn
Sep 14, 2012
The healthcare Industry in the United States works as a separate entity and many of the healthcare services are privately owned and operated. Healthcare has always been a topic of debate for the U.S. government because policy makers argue that the system is not delivering value for money services. In fact government is spending twice as much on life expectancy and infant mortality rate...
|
|
Now At-Home TB Diagnosis Looks Possible
Sep 14, 2012
According to a recent research published in Nature Chemistry, scientists have revealed that a certain sensitive fluorescent molecule is capable of efficiently and quickly tracing TB (tuberculosis) bacteria from the sputum samples.
The year 2010 registered approximately 4000 deaths per day because of TB. TB diagnosis takes a few weeks and the disease being contagious puts others at...
|
|
China Economy Gets USD 157 Billion Stimulus with Sanction for 60 Infrastructure Projects
Sep 14, 2012
Seen as a much required economical stimulus to revive the economy stuck in the worst slowdown in the past three years, China has approved 60 different infrastructure projects valued at more than USD 150 billion. Immediately after the official confirmation of the decision, stocks of major industries such as cement and steel have seen a rise on hopes generated by plans to build ports, highways,...
|
|
Battling against flu, vaccination necessary for health workers
Sep 14, 2012
To battle against flu this season, health officials have tightened their resolve to get more health care workers vaccinated. Flu is a disease that transfers from one to another. Keeping this in mind health officials want every worker in the health care department to get vaccinated. By doing this, it will lessen the chances of others getting affected by this disease.
Health officials...
|
|
Japan to Cut Import Duties on Indian Generic Drugs Imports
Sep 14, 2012
The 44th ASEAN Economic Ministers Meeting held last week in Cambodia has certainly brought good news for the Indian Pharmaceuticals industry. During the meeting on the sidelines of the 44th ASEAN Economic Ministers Meet, Indian Commerce and Industry Minister Anand Sharma brought up the issue with his Japanese counterpart Yukio Edano. Yukio Edano is the minister of economy, trade and Industry...
|
